Compare The Vita Coco Company Inc (COCO) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Vita Coco Company Inc vs Charles River Laboratories Intl. Inc — how do they compare? The Vita Coco Company Inc trades at $64.43 (market cap $3.63B), while Charles River Laboratories Intl. Inc trades at $282.01 (market cap $13.22B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3.6× The Vita Coco Company Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, The Vita Coco Company Inc nearer its low. Which is the better fit depends on your goals.
| COCO | CRL | |
|---|---|---|
Market Cap | $3.63B | $13.22B |
Sector | Technology | Health |
52-Week High | $84.02 | $277.00 |
52-Week Low | $32.37 | $145.57 |
Enterprise Value | $3.37B | $16.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The Vita Coco Company (COCO) trades at $62.25, down 2.92% over 24 hours, with a bullish technical signal driven by oversold RSI readings and support near $62. Fundamentally, Q2 2026 earnings beat expectations with EPS of $0.82 versus $0.56 estimated, while revenue grew 28% year-over-year to $216 million. The company raised full-year 2026 guidance, reflecting strong demand and the Copra acquisition.
Outlook remains positive with 60% analyst buy ratings and an $80.67 consensus price target, implying ~30% upside. Key risks include margin pressure from rising costs and capacity constraints. Growth catalysts include international expansion and health-focused innovation in the beverage sector.
Charles River Laboratories (CRL) trades at $267.49, up 0.75% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.02 versus $2.77 expected, and raised full-year guidance. Despite negative net income margins and high valuation multiples, analyst sentiment remains overwhelmingly positive with 72% buy ratings.
CRL shows operational strength with consistent earnings beats and improved demand, yet faces risks from high debt and profitability challenges. The consensus price target of $277.29 suggests modest upside, but investors must weigh growth prospects against valuation concerns and macroeconomic pressures on biotech spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
